These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 25776511)
1. Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate. Fan M; Yang D; Liang X; Ao J; Li Z; Wang H; Shi B Biomed Pharmacother; 2015 Mar; 70():268-73. PubMed ID: 25776511 [TBL] [Abstract][Full Text] [Related]
2. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice. Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425 [TBL] [Abstract][Full Text] [Related]
4. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. Kopansky E; Shamay Y; David A J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249 [TBL] [Abstract][Full Text] [Related]
5. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery. Fan M; Liang X; Yang D; Pan X; Li Z; Wang H; Shi B J Drug Target; 2016; 24(2):111-9. PubMed ID: 26176268 [TBL] [Abstract][Full Text] [Related]
7. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment. Zou Y; Xia Y; Meng F; Zhang J; Zhong Z Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299 [TBL] [Abstract][Full Text] [Related]
8. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893 [TBL] [Abstract][Full Text] [Related]
9. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Song S; Liu D; Peng J; Sun Y; Li Z; Gu JR; Xu Y Int J Pharm; 2008 Nov; 363(1-2):155-61. PubMed ID: 18692120 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643 [TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro anti-cancer activities and enhanced cellular uptakes of EGF fragment decorated doxorubicin nano-aggregates. Park S; Yoo HS Int J Pharm; 2010 Jan; 383(1-2):178-85. PubMed ID: 19732814 [TBL] [Abstract][Full Text] [Related]
12. Cellular delivery of doxorubicin mediated by disulfide reduction of a peptide-dendrimer bioconjugate. Burns KE; Delehanty JB Int J Pharm; 2018 Jul; 545(1-2):64-73. PubMed ID: 29709616 [TBL] [Abstract][Full Text] [Related]
13. Target-specific near-IR induced drug release and photothermal therapy with accumulated Au/Ag hollow nanoshells on pulmonary cancer cell membranes. Noh MS; Lee S; Kang H; Yang JK; Lee H; Hwang D; Lee JW; Jeong S; Jang Y; Jun BH; Jeong DH; Kim SK; Lee YS; Cho MH Biomaterials; 2015 Mar; 45():81-92. PubMed ID: 25662498 [TBL] [Abstract][Full Text] [Related]
14. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009 [TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein peptide-combined DNA nanocomplex as an efficient anticancer drug delivery vehicle. Zhang N; Tao J; Hua H; Sun P; Zhao Y Eur J Pharm Biopharm; 2015 Aug; 94():20-9. PubMed ID: 25960329 [TBL] [Abstract][Full Text] [Related]
16. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer. Vega J; Ke S; Fan Z; Wallace S; Charsangavej C; Li C Pharm Res; 2003 May; 20(5):826-32. PubMed ID: 12751641 [TBL] [Abstract][Full Text] [Related]
17. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Talelli M; Iman M; Varkouhi AK; Rijcken CJ; Schiffelers RM; Etrych T; Ulbrich K; van Nostrum CF; Lammers T; Storm G; Hennink WE Biomaterials; 2010 Oct; 31(30):7797-804. PubMed ID: 20673684 [TBL] [Abstract][Full Text] [Related]
18. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy. Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168 [TBL] [Abstract][Full Text] [Related]
19. Effect of intratumoral injection on the biodistribution and therapeutic potential of novel chemophor EL-modified single-walled nanotube loading doxorubicin. Liu H; Xu H; Wang Y; He Z; Li S Drug Dev Ind Pharm; 2012 Sep; 38(9):1031-8. PubMed ID: 22794192 [TBL] [Abstract][Full Text] [Related]
20. Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Kuo YC; Liang CT Colloids Surf B Biointerfaces; 2011 Jul; 85(2):131-7. PubMed ID: 21411296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]